Reshaping the HIV treatment and prevention landscape
New GSK:
new ambitions
for patients and
shareholders
More than 5% sales and 10% adjusted operating profit CAGR 2021-26
Progressive dividend policy
Pipeline drives growth through DTG LOE, more than £33bn sales by 2031
Prioritise Vaccines and Specialty Medicines,
maximise scientific opportunities in prevention and treatment
Optimise General Medicines portfolio for profitability and cash
Balance sheet strengthened supporting investment in growth
Operate sustainably with leading ESG performance
Positively impact health of more than 2.5 bn people in next 10 years
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See
basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of
new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.
DTG dolutegravir; LoE loss of exclusivity
24View entire presentation